FTY720: altered lymphocyte traffic results in allograft protection.
Brinkmann
V
V
Novartis Pharma AG, Transplantation Research, WSJ-386.1.01, CH-4002 Basel, Switzerland.
Pinschewer
D D
DD
Feng
L
L
Chen
S
S
D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D018925:Chemokines / Q000276:immunology; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000494:pharmacology; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy; D000068876:Fingolimod Hydrochloride; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology; D016381:Islets of Langerhans Transplantation; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D023421:Models, Animal; D011409:Propylene Glycols / Q000494:pharmacology*; D012449:Safety; D013110:Sphingosine / Q000031:analogs & derivatives; D014184:Transplantation, Homologous
D018925:Chemokines; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D016572:Cyclosporine; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine